QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Forecast, Price & News

$5.40
-0.12 (-2.17%)
(As of 04:13 PM ET)
Compare
Today's Range
$5.28
$5.50
50-Day Range
$5.52
$9.39
52-Week Range
$5.28
$15.90
Volume
1.09 million shs
Average Volume
986,765 shs
Market Capitalization
$736.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33

Cytek Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
169.9% Upside
$14.33 Price Target
Short Interest
Bearish
10.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.03mentions of Cytek Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$995,610 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.07) to $0.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

744th out of 969 stocks

Analytical Instruments Industry

21st out of 29 stocks


CTKB stock logo

About Cytek Biosciences (NASDAQ:CTKB) Stock

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Price History

CTKB Stock News Headlines

Cytek Biosciences (NASDAQ:CTKB) Shares Down 6.1%
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Massive Insider Trade At Cytek Biosciences
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
What Wall Street expects from Cytek Biosciences,'s earnings
Cytek Biosciences up 6% $50M buyback
Why Shares of Cytek Biosciences Dropped This Week
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
699
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.33
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+169.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$2.58 million
Pretax Margin
-5.51%

Debt

Sales & Book Value

Annual Sales
$164.04 million
Cash Flow
$0.07 per share
Book Value
$3.16 per share

Miscellaneous

Free Float
114,679,000
Market Cap
$724.07 million
Optionable
Not Optionable
Beta
0.60
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 59)
    Pres, CEO & Chairman
    Comp: $964.21k
  • Dr. Ming Yan Ph.D. (Age 60)
    CTO & Director
    Comp: $616.26k
  • Ms. Valerie T. Barnett J.D. (Age 48)
    Gen. Counsel & Corp. Sec.
    Comp: $535.98k
  • Mr. Patrik Sebastian Jeanmonod (Age 57)
    Chief Financial Officer
  • Mr. Chris Williams (Age 54)
    Chief Operating Officer
  • Mr. Paul D. Goodson
    Head of Investor Relations
  • Dr. Allen B. Poirson Ph.D. (Age 63)
    Sr. VP of Bus. & Corp. Devel.
  • Dr. Philippe Busque Ph.D.
    Sr. VP of Global Sales & Services
  • Ms. Connie Wedel
    Chief People Officer
  • Mr. Melik Ulusu
    Sr. VP of Operations & Integrated Supply Chain













CTKB Stock - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price forecast for 2023?

4 brokerages have issued 12-month target prices for Cytek Biosciences' shares. Their CTKB share price forecasts range from $14.00 to $15.00. On average, they expect the company's stock price to reach $14.33 in the next year. This suggests a possible upside of 169.9% from the stock's current price.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2023?

Cytek Biosciences' stock was trading at $10.21 at the beginning of the year. Since then, CTKB stock has decreased by 48.0% and is now trading at $5.31.
View the best growth stocks for 2023 here
.

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CTKB earnings forecast
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.02) EPS for the quarter. The business had revenue of $49.69 million for the quarter, compared to analyst estimates of $46.52 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 0.37% and a negative net margin of 3.31%.

What ETF holds Cytek Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

What guidance has Cytek Biosciences issued on next quarter's earnings?

Cytek Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$220.00 million, compared to the consensus revenue estimate of $209.22 million.

When did Cytek Biosciences IPO?

(CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

What is Cytek Biosciences' stock symbol?

Cytek Biosciences trades on the NASDAQ under the ticker symbol "CTKB."

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytek Biosciences' stock price today?

One share of CTKB stock can currently be purchased for approximately $5.31.

How much money does Cytek Biosciences make?

Cytek Biosciences (NASDAQ:CTKB) has a market capitalization of $724.07 million and generates $164.04 million in revenue each year. The company earns $2.58 million in net income (profit) each year or ($0.04) on an earnings per share basis.

How many employees does Cytek Biosciences have?

The company employs 699 workers across the globe.

How can I contact Cytek Biosciences?

The official website for the company is www.cytekdev.com. The company can be reached via phone at 877-922-9835 or via email at investors@cytekbio.com.

This page (NASDAQ:CTKB) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -